Introduction
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation and subsequent progressive destruction of the joints. The causes of RA have not been clearly determined, but it is believed that CD4+ T-cell-mediated autoimmune responses play a critical role in the pathogenesis of RA. IFN-g-producing Th1 cells appear to be pivotal in the development of autoimmune arthritis in both humans and animal models, whereas Th2 cells that secrete IL-4 or IL-10 are protective in animal models. 1 Modulation of the CD4+ response by immunodepletion has been successful in treating a mouse model of RA, type II collagen-induced arthritis (CIA), 2 although the same strategy has been less effective in treating RA. 3 Depletion of CD4+ T cells is not an ideal treatment, as it could lead to systemic immune suppression. Thus, inhibition of specific cytokines and/or their receptors is believed to be a more viable approach. 4 There is strong evidence that TNF is a good candidate to inhibit. 5 Administration of neutralizing anti-TNF monoclonal antibodies to synovial cell cultures leads to a reduction in expression of IL-1, IL-6, IL-8 and GM-CSF. [6] [7] [8] [9] [10] RA has been efficiently controlled by systemic administration of anti-TNF monoclonal antibodies. 11, 12 However, this approach is antigen nonspecific and can potentially lead to systemic immune suppression. 13, 14 The occurrence of tuberculosis in patients receiving TNF neutralizing agents is four-fold higher than that in the general population. 15 The majority of these patients presented with disseminated disease and extrapulmonary tuberculosis, features that are associated with immune suppression. On the basis of these studies, it has been recommended that patients be screened for latent tuberculosis prior to treatment. 16 Therefore, it would be preferable to deliver any therapeutic agent in a controlled localized fashion. Robbins et al 17 have successfully delivered soluble TNF receptor by intra-articular injection of adenoviral vectors. However, there are concerns surrounding the immunogenicity of adenoviral vectors, as well as the discomfort patients would have to suffer undergoing multiple injections into the joints. The same group has also successfully used dendritic cells transduced ex vivo with adenoviral vectors encoding IL-4.
of circumventing these problems, as patient-derived cells will be nonimmunogenic, and can be retrovirally transduced ex vivo, then delivered to the patient at a point distant from the site of disease. These cells will then be able to home in to the sites of inflammation and deliver their immune modulating products. [19] [20] [21] [22] [23] This procedure has been demonstrated in a passive transfer model of CIA in which splenocytes taken from a mouse suffering from CIA can induce CIA in a SCID recipient. 24, 25 If these splenocytes are transduced ex vivo with a retrovirus encoding the soluble TNF receptor, they fail to induce disease. However, although these studies are interesting from the viewpoint of elucidating the biology of the system, they cannot be considered the basis of a therapeutic approach, as the cellular delivery vehicles are also responsible for inducing disease.
Autoantigen-specific CD4+ T cells have organ-specific homing and retention properties. We have previously demonstrated that collagen type II (CII)-reactive CD4+ primary T cells and T-cell hybridomas, retrovirally transduced to express immune-regulatory proteins, can be used to deliver and express transgenes locally in the inflamed joint. 21 We and others have demonstrated that expression of immunoregulatory proteins, such as IL-4 and IL-12p40, by autoantigen-specific CD4+ T lymphocytes (as well as by T-cell hybridomas) retrovirally transduced to express regulatory proteins could ameliorate the clinical signs of experimental autoimmune encephalomyelitis (EAE) and CIA after adoptive cell transfer. 23, [26] [27] [28] These previous reports also provided evidence that homing to and antigen-specific retention at the site of inflammation are necessary for the therapeutic effect. Given the similarity in results obtained using primary T cells and hybridomas, we have continued to use T-cell hybridomas for the purpose of rapidly and reliably testing potential therapeutic gene products as hybridomas can be easily generated and transduced in sufficient numbers for this purpose.
TNF has been shown to play a key role in the development and maintenance of proinflammatory T helper cell type 1 (Th1) responses in autoimmune disease. 5, 23 Both antibodies and soluble receptors have been used to block TNF activity. [29] [30] [31] Although monoclonal antibodies have been shown to be effective neutralizing agents in vivo, they are not suitable candidates for delivery by gene therapy because of their heteromultimeric structure, requiring expression of both the heavy and light immunoglobulin chains. However, it is possible to fuse the variable regions from the heavy and light chains into a single polypeptide that retains the binding properties of the parent antibody. Such singlechain antibody variable region fragments (scFv) have been widely used as dominant-negative effectors of protein function. [32] [33] [34] [35] [36] [37] Here we demonstrate that scFvs derived from a TNF neutralizing monoclonal antibody can themselves neutralize TNF in vitro. We also show that these scFvs can be delivered in vivo to mice with CII-induced arthritis and block progression of disease, leading to local changes in cytokine expression patterns without affecting systemic immune responses. These changes provide evidence for a physiological change in the joints that can be attributed to blockade of TNF activity.
Results
Generation of constructs and cell lines scFvs were generated by overlapping PCR (Figure 1a ) and cloned into the retroviral vector pGCy. This vector has a yellow fluorescent protein (YFP) surrogate marker for transgene expression. Ecotropic retrovirus was produced from transiently transfected Phoenix-E producer cells and used to infect A2 CII-specific T-cell hybridomas. Infected cells were sorted by FACS for high YFP and Vb8.2 T-cell receptor (TCR) expression. It is necessary to sort for TCR expression as the hybridoma fusion partner does not express TCR. Sorting for Vb8.2 allows us to select for cells with stable TCR expression. Immunoprecipitation and Western blot (Figure 1b) confirmed scFv expression. The half-lives of scFvs TN3 and TN3-Ck were determined to be 2.2 and 5. 3 between the two variable domains. The native immunoglobulin secretion signal (ss) was preserved at the N-terminus, while an influenza haemagglutinin epitope tag was added to the C-terminus. TN3-Ck varied from TN3 by the addition of the kappa chain constant region between the VL domain and the HA epitope tag. (b) Expression of scFvs from A2 T-cell hybridomas. A2 Tcell hybridomas were infected with retroviral constructs expressing scFv constructs TN3 and TN3-Ck plus a YFP surrogate marker. Immunoprecipitations using an anti-influenza haemagglutinin antibody were performed on media conditioned by retrovirally transduced A2 cells for 24 h. scFvs were detected by Western blotting. (c) Determination of scFv stability in tissue culture. scFv producer cells were cultured at 1 Â 10 6 cells per ml for 24 h, after which the cells were removed and the media incubated at 371C for a further 8 h. scFv levels were determined by Western blotting. The half-lives of TN3 and TN3-Ck were calculated to be 2.2 and 5.5 h, respectively, on the basis of densitometry analysis of the bands on the blot.
Localized anti-TNF cellular therapy for arthritis R Smith et al Biological activity of scFvs TN3 and TN3-Ck In vitro activity. In order to demonstrate that the scFv constructs could bind TNF, putative scFv-TNF complexes were coimmunoprecipitated using an anti-HA epitope tag monoclonal antibody. Western blotting of the resulting complex using a primary anti-TNF antibody demonstrated that the scFvs could bind TNF (Figure 2a) . TNF activity can be measured by its ability to induce the apoptosis of certain transformed cell lines in the presence of a protein synthesis inhibitor such as cycloheximide. Serial dilutions of TNF were made in supernatants taken from sorted, transduced A2 hybridomas, seeded at 1 Â 10 6 cells per ml for 24 h. Supernatant taken from the pGCy vector control A2 hybridomas was also spiked with various concentrations of a neutralizing anti-murine TNF monoclonal antibody (clone XPM6, Pharmingen) (Figure 2b) . Although a certain amount of apoptosis in the WEHI-164 fibrosarcoma cells was because of endogenous TNF in the A2 hybridoma supernatants (20 pg/ml TNF as determined by ELISA), both scFvs showed TNF neutralizing activity. Both TN3 and TN3-Ck scFv conditioned media was comparable to approximately 50 ng/ml anti-TNF monoclonal antibody.
In an alternative in vitro assay, supernatants from 293 T cells transiently transfected with pGCy.TN3, pGCy.TN3-Ck and pGCy were harvested and incubated with varying concentrations of TNF. When increasing concentrations of TNF in pGCy control supernatant were applied to Jurkat T cells that had been transiently transfected with an NF-kB-dependent luciferase reporter construct, luciferase expression increased in direct proportion with TNF concentration (Figure 2c ). Incubation with pGCy.TN3 supernatant caused a 50% reduction in luciferase expression at 10 ng/ml TNF, while incubation with pGCy.TN3-Ck supernatant completely blocked TNF-induced luciferase expression within the ranges of TNF concentration studied here. The slight drop in luciferase activity below that of the negative control in the TN3-Ck incubations is because of the scFv inactivating endogenous TNF produced by the 293 T cells used in this experiment (these cells secrete 20 pg/ml TNF as determined by ELISA).
In vivo activity. In order to assess the activities of our scFv constructs in vivo, the CIA mouse model was used. TNF has previously been shown to have a significant contribution to pathology in both murine and human arthritis 4, 5, 38 . Retrovirally transduced (1 Â 10 6 ), sorted A2 hybridomas were adoptively transferred by tail vein injection 1 day before booster immunization with CII in IFA. It has been shown previously that untransduced A2 6 cells per ml for 24 h, after which the cells were removed and the media incubated overnight at 41C with 710 ng/ml recombinant murine TNF. Putative scFv-TNF complexes were immunoprecipitated using an anti-influenza haemagglutinin antibody, and TNF was detected by Western blotting using an anti-TNF antibody. TNF can only be detected if either TN3 or TN3-Ck scFv is present, to link the TNF to the anti-influenza haemagglutinin immunoprecipitation antibody. (b) Inhibition of TNF-mediated apoptosis of a murine fibrosarcoma cell line by TN3 and TN3-Ck scFvs, and an anti-TNF neutralizing monoclonal antibody. Increasing concentrations of TNF in the presence of cycloheximide induce apoptosis of WEHI-164 murine fibrosarcoma in a dose-dependent fashion. Cell survival was measured using the MTT assay, with absorbance at 570 nm being directly proportional to the number of viable cells. Apoptosis induction can be blocked by addition of the anti-TNF neutralizing antibody XPM-6 (Pharmingen). Using medium conditioned by scFv producer cells grown at 1 Â 10 6 cells per ml for 24 h, a TNF neutralizing activity equivalent to between 25 and 50 ng/ml XPM-6 monoclonal antibody is observed. This is not seen when media conditioned by A2 cells carrying the pGCy vector control are used. All data points were repeated in quadruplicate. (c) Inhibition of TNF-induced expression from an NF-kB-dependent luciferase reporter in Jurkat T cells. Jurkat cells transiently cotransfected with an Igk promoter-luciferase reporter construct (which has multiple NF-kB response elements) and a pWZL-lacZ transfection control (with lacZ under the control of a constitutive retroviral promoter) respond to TNF in a dose-dependent fashion by upregulating luciferase expression. This induction can be blocked by incubating the reporter cells in medium conditioned by scFv producer cells grown at 1 Â 10 6 cells per ml for 24 h. Relative to reporter cells stimulated by TNF in medium conditioned by A2 cells carrying the pGCy vector control, incubation with TN3 scFv conditioned medium results in a 50% reduction in luciferase activity at 10 ng/ml TNF. Incubation with TN3-Ck conditioned medium completely blocks TNF luciferase expression up to a dose of 10 ng/ml.
Localized anti-TNF cellular therapy for arthritis R Smith et al hybridomas do not exacerbate or ameliorate CIA. 21 Following the booster immunization, disease progression and incidence were followed for 30 days ( Figure 3 ). A slight reduction in clinical disease severity was seen in the animals adoptively transferred with hybridomas transduced to express TN3. In the group of animals treated with hybridomas transduced with pGCy.TN3-Ck, however, a significant reduction in disease severity was observed relative to controls. The reduced mean disease severity in the treatment groups was because the majority of animals did not develop any signs of arthritis, while the majority of animals in the control groups exhibited severe disease. There was also a reduction in disease incidence in the pGCy.TN3 and pGCy.TN3-Ck treatment groups relative to controls. RT-PCR showed that at 7 days postcollagen booster injection, scFv expression could be detected in the paws but not the spleens of animals that had received A2-pGCy.TN3 or A2-pGCy.TN3-Ck (Figure 4a ). The RT-PCR conditions used were sensitive enough to detect YFP from single A2-pGCy.TN3-Ck cells (data not shown). Transgene expression was clearly detected 7 and 14 days postinjection (Figure 4b ). Expression was lost over time, although in one sample (group TN3-Ck, disease score 2) YFP expression was detected as late as 55 days postinjection. There was no correlation between loss of YFP expression and severity of disease in the paw. No anti-scFv antibodies were found in serum by ELISA (data not shown). No structural abnormalities that could be attributed to tumour formation by the hybridomas were observed.
The YFP expression in paw tissues correlated with increased intra-articular expression of chemokines, in particular SDF-1, MIP-1b and MDC. Using quantitative RT-PCR, we found differential chemokine expression related directly to disease severity. Chemokine levels peaked on day 7 after booster immunization (Figure 4c) . Previous studies have shown that the A2 hybridomas express the relevant chemokine receptors, CXCR4, CCR7 and CCR4, and exhibit strong chemotaxis in response to SDF-1, MIP-3b and MDC in vitro. 23 Taken together, these results demonstrate that adoptive cellular gene therapy leads to localized expression of the therapeutic transgenes. As a result of this local delivery, TN3 and TN3-Ck were found to elicit local effects in the paws. RT-PCR was used to determine relative levels of IL-1, IL-1Ra, IL-4, IL-6, IFN-g and TNF in total RNA extracted from paws grouped on the basis of disease severity ( Figure 5 ). Of these cytokines, only IL-6 showed a variable pattern of expression in response to scFv treatment. IL-6 expression is directly regulated by TNF, 39 and is observed in severely inflamed paws (score 4) in both the untreated group and the pGC-y vector control group. In contrast, no IL-6 expression was detected in even the most inflamed paws in the groups that received TN3 and TN3-Ck scFv treatments. This change was seen from days 7 to 30. At day 55 no IL-6 expression was detected in any samples.
In order to exclude possible systemic immune effects of our adoptive cellular gene therapy, cells were harvested from the spleen and draining lymph nodes (DLN) of five animals in each treatment group at 7, 14 6 retrovirally transduced A2 T-cell hybridomas, sorted on the basis of high YFP and TCR expression, were injected via the tail vein. Three groups of mice received the transduced hybridomas. In these groups the hybridomas were infected with either the pGCy vector control, pGCy.TN3 or pGCy.TN3Ck. In addition, there was also a group which received no treatment. For all these groups n¼5. Over the next 30 days disease progression was measured on the basis of paw inflammation, which was scored on a scale of zero to four. Treatment with A2-pGCy.TN3Ck produced a significant reduction in disease, as determined by the Mann-Whitmann test (Po0.05). Both disease progression (a) and disease incidence (b) are shown. Error bars are expressed as standard error of the mean.
Localized anti-TNF cellular therapy for arthritis R Smith et al and 30 days post-CII booster injection. The isolated cells were cultured in vitro either in the presence or absence of denatured CII. Cell proliferation was determined by incorporation of tritiated thymidine over 72 h following stimulation ( Figure 6 ). In the spleen there was no significant proliferative response to CII stimulation. In the DLN, a slight increase in proliferation is seen in response to CII. At days 14 and 30, this proliferative response was reduced in the TN3 and TN3-Ck treatment groups relative to the untreated and pGCy vector control groups, although not at a level that was statistically significant. Cytokine profiles in response to stimulation with CII were determined ex vivo. Splenocytes and lymphocytes were cultured for 72 h with or without 50 mg/ml denatured CII. ELISA was used to determine IL-2, IL-4, IL-10, IFN-g and TNF levels ( Figure 7 ). No significant difference was seen between the four treatment groups in terms of mean cytokine profile in either the spleen or DLN following stimulation with CII. Taken in conjunction with the proliferation data, T-cellmediated delivery of these agents mediate a reduction in disease occurrence and severity in the paws without demonstrable systemic downregulation of immune function.
Discussion
We have demonstrated that scFvs designed to bind TNF can neutralize TNF in vitro, and be used successfully to prevent development of an inflammatory autoimmune disease in vivo. We have achieved this therapeutic effect by delivering the scFv proteins directly to the site of disease using autoantigen-reactive T-cell hybridomas that home specifically to the inflamed paws in mice with CIA.
Prior limitations in other therapies drove our adoption of this approach. Blockade of TNF using systemically administered monoclonal antibodies has been successful at blocking RA, but potentially leaves patients vulnerable to infection and malignancy.
13,14 Therefore, we engi- . Groups for which no paws of a particular score were available are indicated (*). Although YFP expression declines over time, in one group (TN3-Ck, score 2) YFP can still be detected up to 55 days after hybridoma injection. (c) Chemokine expression is directly correlated to the degree of inflammation in the paw on day 7. Expression of chemokines SDF-1, MIP-3b and MDC was quantified by real-time PCR in total RNA extracted from paws grouped by how inflamed the paws were (0¼no inflammation, 2¼disease score of 1 or 2, 4¼disease score of 3 or 4). A2 hybridomas have previously been shown to have a chemotactic response to these chemokines in vitro. Chemokine levels were highest on day 7, decreasing to day 30 (data not shown). . Groups for which no paws of a particular score were available are indicated (*). IFN-g, TNF, IL-1, IL-1Ra and IL-4 did not show any variation between samples (data not shown). In contrast, IL-6 was only detected in highly inflamed paws (score 4) in the untreated group and the group that received A2-pGCy vector control up to day 30. IL-6 expression could not be detected in either of the scFv treatment groups. By day 55, no IL-6 could be detected in any group.
Localized anti-TNF cellular therapy for arthritis R Smith et al neered CII-specific CD4+ T-cell hybridomas, which had previously been shown to home to the paws of arthritic mice, 21 to secrete one of two anti-TNF scFv constructs, TN3 and TN3-Ck, locally rather than systemically. Of the two constructs, TN3-Ck had a more pronounced therapeutic effect when delivered in this fashion. Based on in vitro data, TN3 and TN3-Ck have comparable TNFneutralizing activity, although addition of the Ck domain increases the stability of the scFv relative to the basic scFv structure used in TN3. However, as we could not detect scFv protein in vivo, we cannot be certain that this is the reason for the increased efficacy we observe. Longterm expression does not appear to be a problem, at least within the time scale of this study, as transgene expression could be detected as late as 55 days postinjection by RT-PCR. The chemokines SDF-1, MIP3b and MDC, to which A2 hybridomas show chemotaxis in vitro, 23 were detected in diseased paws, suggesting that chemokine expression in early disease stages could be an important component allowing attraction of the therapeutic hybridoma cells to the sites of inflammation. No gross abnormalities that could be attributed to the hybridomas establishing tumours were observed. Although some loss of expression was seen in some samples, this was not correlated in any way to the degree of inflammation present in the paw. In addition, no antiscFv neutralizing antibodies could be detected in serum as late as 30 days, a time by which it would be expected that any antibody response could be detectable.
Analysis of cell proliferation and cytokine secretion in response to CII stimulation is supportive of our hypothesis that our treatment regime does not induce systemic immune changes. No significant changes in splenocyte proliferative response were observed between any of the treatment groups, although a diminution of CII-induced proliferation was seen at day 14 in the DLN taken from both the TN3 and TN3-Ck treatment groups relative to the untreated and pGCy vector control treatment groups. This limited and transient response in the DLN is likely because of their proximity to the sites of disease. In addition, no significant changes in cytokine profile between all treatment groups were seen in either the spleen or DLN. This differs from what is observed following systemic administration of anti-TNF monoclonal antibodies, where changes in the levels of inflammatory cytokines and acute-phase proteins are seen. 40 . Are there any physiological changes in the paws as a result of scFv treatment? Clearly, we can see that treatment with both TN3 and, to a much greater extent, with TN3-Ck prevents development of CIA. Cytokine expression within the paws was determined using RT-PCR, which revealed that of the cytokines studied only IL-6 showed any change in expression. IL-6 expression has been shown previously to be elevated in RA, and in vitro can be stimulated by TNF. IL-6 was only detectable in highly inflamed paws (disease score¼4) from the untreated and pGCy vector control groups. It was not Figure 6 Proliferation of splenocytes and lymphocytes in culture to collagen. Spleen and DLN were harvested from five animals at days 7, 14 and 30. Single cell suspensions were produced. Isolated cells were cultured for 72 h at a density of 5 Â 10 5 cells per ml with 0, 50 or 100 mg/ml bovine CII collagen. Cell proliferation was determined by 3 H-thymidine incorporation. Fold cell proliferation in response to collagen stimulation was determined relative to cells that received no stimulation. All assays were repeated in triplicate for each animal. The mean fold proliferation for each group of five animals is shown here. No statistically significant variation is seen between the untreated and pGCy vector control groups and the TN3-and TN3-Ck scFv treatment groups at any time point.
Localized anti-TNF cellular therapy for arthritis R Smith et al detectable in any paw samples from both the TN3 and TN3-Ck treatment groups at days 7 and 30. It should also be noted that IL-6 was not detectable in any spleen samples. We believe that this lack of local IL-6 expression in the scFv treatment groups is directly attributable to the blockade of TNF activity within the paws. Reduction in serum IL-6 has been observed following systemic administration of the anti-TNF monoclonal antibody cA2 in RA. 40 This study provides further in vivo evidence that TNF is regulating IL-6 expression in the synovial tissue. It is interesting that we only observed scFv-dependent changes in IL-6 expression in the paw; no IL-6 expression could be detected by RT-PCR in the spleen. The results also suggest that an anti-IL-6 scFv might contribute to disease amelioration if delivered locally.
Despite the physiological response being observed, some animals in the treatment groups still developed arthritis. This leads us to believe that pathways other than TNF-mediated inflammation play an important role in the development of arthritis in the CIA model. This is supported by the observation that IL-6 expression is undetectable in any samples by day 55. This suggests that IL-6 plays a role in establishing the inflammatory autoimmune response at an early stage in disease. By day 55, we hypothesize that other pathways may be playing a role in maintaining disease. These pathways may themselves be responsible for establishing disease in the TN3-and TN3-Ck-treated animals, which show some diseased paws, but no IL-6 expression. IL-1 is a possible candidate for an alternative mediator. Probert et al 41 have demonstrated that administration of an anti-IL-1 receptor antibody prevents CIA. In our study, we see no difference in levels of IL-1 or IL-1Ra by RT-PCR in the paws of any of the treatment groups (data not shown). This contradicts observations seen in earlier studies, although these studies were based on systemic, rather than local, treatment. 42, 43 In a previous study, we have shown that administration of IL-12-p40 using a similar adoptive cell therapy approach to that described here can lead to blockade of disease development. 21 However, this earlier study did not examine cytokine profiles within the paw, so we cannot theorize by what mechanism this agent blocked arthritis. Preliminary studies have shown that TN3-Ck scFv and IL-12-p40 cannot treat existing disease when given separately, but when administered in combination can prevent progression of existing disease (Tarner, Smith et al, unpublished data). This supports the hypothesis of multiple pathways being involved in maintaining the autoimmune state. Further studies Figure 7 Cytokine profiles of cells isolated from the DLN and spleen. Five mice in each treatment group were killed at days 7, 14 and 30, the DLN and spleen removed, and single cell suspensions produced. Isolated cells were cultured for 72 h at a density of 5 Â 10 5 cells per ml both with 50 mg/ml bovine CII collagen (+) and without (À). Following stimulation, cell supernatants were harvested and tested by ELISA for IL-2, IL-4, IL-10, IFN-g and TNF. No significant difference in the levels of any of the cytokines was seen between all the treatment groups. One outlying point in the TN3-Ck group was seen at day 30 in the IFN-g ELISA (*). This animal was the sole individual in the treatment group that developed disease.
Localized anti-TNF cellular therapy for arthritis R Smith et al aimed at elucidating the cytokine profiles within the paws of these animals are under way and will help to underscore the specific biological mechanism at work. In conclusion, we have shown that antigen-specific T lymphocytes can deliver a TNF neutralizing agent specifically to the sites of disease in CIA. Adoptive cellular gene therapy allows long-term expression of the therapeutic transgene, which in turn leads to a detectable physiological response limited to the tissues affected by disease. This is potentially significant given the side effects that have been seen in patients receiving systemic anti-TNF therapies. In addition, this method of localized transgene delivery can be used as a tool for the elucidation of the mechanisms by which an autoimmune response is propagated within a diseased tissue.
Materials and methods

Mice
Male DBA/1 LacJ (H-2q) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and were used at 7-10 weeks of age. CII-specific TCR transgenic (tg) mice on the SWR (H-2 q ) background were kindly provided by Warren C Ladiges (University of Washington, Seattle, WA, USA).
Construct and cell lines
scFvs were derived from hamster IgG1 monoclonal antibody TN3.19.1, which has anti-murine TNF activity. Heavy and light chain variable regions and kappa chain constant region were amplified from plasmid pDGV118 (a gift of N Weir, Celltech, Slough, UK) using primers VH5 (CCAAGTGAATTCATGGCCCTGTTTGCCTCCTCA), VH3 (GCCGCCACCCGACCCACCACCGCCCGAGCC ACCGCCACCTGAGGAAGACGGTGAACTATGGTTCC), VL5 (GGTGGCTCGGGCGGTGGTGGGTCGGGTGGCG GCGGATCTGATATTGTGATGACCCAGTCTCCA), VL3 (AATGCACCGCGGCTAAGCGTAATCTGGAACATCG TATGGGTACCGTTTTATCTCGAGCTTGGTCCC), Ck5 (CCACACACGTTCGGAGGTGGGACC) and Ck3 (AA TGCACTCGAGCTAAGCGTAATCTGGAACATCGTAT GGGTAACACTCATTCCTGTTGAAGC). Variable region domains were assembled by overlapping PCR using external primer pairs to form scFv constructs TN3 and TN3-Ck (Figure 1a ). These were then cloned into the SacII site in the retroviral vector pGCy, 21, 28 upstream of the surrogate marker YFP. Retroviruses were generated by transient transfection of vector constructs pGCy, pGCy.TN3 and pGCy.TN3-Ck into Phoenix-E producer cells as previously described. 21 Viral supernatants were used to infect the CII-reactive T-cell hybridoma line A2. 18, 21 Infected cells were sorted by FACS for high YFP and TCR Vb8.2 expression. scFv expression was confirmed by Western blotting.
scFv stability A2 T-cell hybridoma cells, expressing TN3 or TN3-Ck, were cultured at a density of 1 Â 10 6 cells per ml for 24 h in RPMI, 5% FCS. The cells were then removed, and the cell-free supernatant was incubated at 371C. Samples were taken at 0, 0.5, 1, 2, 4, 6 and 8 h, immediately mixed with SDS-polyacrylamide gel (PAGE) denaturing gel loading buffer and frozen on dry ice. The complete panel of samples was run on a 15% SDS-PAGE, and Western blotted. The blot was developed using ECL chemiluminescent agent (Amersham).
Biological activity assays
Binding of TNF by the scFvs was determined by coimmunoprecipitation. Supernatants from A2 hybridoma cells retrovirally transduced with pGCy, pGCy.TN3 or pGCy.TN3Ck grown at a density of 1 Â 10 6 cells per ml were incubated for 3 h at 371C with 10 ng/ml recombinant murine TNF. Putative scFv-TNF complexes were immunoprecipitated with an anti-flu haemaggluttinin epitope tag monoclonal antibody and protein-A sepharose beads. The precipitated protein was run on a 15% SDS-PAGE and blotted onto PVDF membrane. The blot was then probed for TNF.
TNF biological activity was determined by two methods: induction of an NF-kB-dependent luciferase reporter construct in Jurkat T cells, and induction of apoptosis in the presence of cycloheximide in WEHI-164 murine fibrosarcoma cells.
Jurkat T cells were transiently cotransfected using DEAE-dextran with pIgk-luc, a luciferase reporter controlled by the Igk promoter (which contains multiple NFkB response elements), and pWZL-lacZ, a constitutively active retroviral vector used as a transfection control. At 12 h post-transfection, the cells were transferred to supernatants taken from 293 T cells transiently transfected with pGCy, pGCy.TN3 or pGCy.TN3-Ck at an efficiency of 80%. The 293 T supernatants had been preincubated for 3 h with varying concentrations of recombinant murine TNF (R&D Diagnostics). The Jurkat T cells were incubated for a further 24 h, then lysed and assayed for luciferase and b-galactosidase activity. Luciferase activity was determined using a proprietary kit (Promega) as was b-galactosidase activity, using a chemiluminescent MUG substrate (Tropix). Luciferase activity was normalized against b-galactosidase activity.
TNF-induced apoptosis in WEHI-164 murine fibrosarcoma cells was determined by MTT assay. Serial dilutions of recombinant murine TNF were produced in A2 hybridoma conditioned medium supplemented with 10 mg/ml cycloheximide (Sigma), generated by culturing A2 hybridomas at 1 Â 10 6 cells per ml for 24 h. A2 hybridomas used were transduced with pGCy, pGCy.TN3 or pGC.TN3-Ck and sorted as described above. Supernatant from A2 hybridomas infected with the vector control pGCy was spiked with varying concentrations of the anti-TNF neutralizing monoclonal antibody clone XMP-6 (Pharmingen). A TNF dilution series was also made in fresh RPMI supplemented with 10% FCS. These TNF dilutions were incubated at 371C for 3 h and then added to WEHI164 cells that had been plated the previous day at a density of 2 Â 10 4 cells per well of a 96-well plate in RPMI supplemented with 10% FCS. Each well contained 100 ml RPMI, 10% FCS and 100 ml TNF dilution. The final concentrations of TNF ranged from 500 to 0.5 pg/ml. The WEHI-164 cells were incubated overnight with the TNF dilutions, after which cell survival was determined by MTT assay. All data points were repeated in quadruplicate.
Endogenous TNF concentration in transduced cell supernatants was determined by ELISA, using a proprietary system (OptEIA mouse TNF set, Pharmingen). Assays were performed in accordance with the manufacturer's instructions.
Localized anti-TNF cellular therapy for arthritis R Smith et al Induction, treatment and assessment of arthritis CIA was induced as described previously. 44 Briefly, DBA/1 LacJ mice were immunized intradermally at the tail base with 200 mg of bovine CII (University of Utah, Salt Lake City, UT, USA) emulsified with an equal volume of complete Freund's adjuvant containing 100 mg of H37Ra Mycobacterium tuberculosis (Difco Laboratories, Detroit, MI, USA). On day 21, the mice were boosted by intradermal injection with 200 mg of bovine CII emulsified with incomplete Freund's adjuvant at the base of the tail. The clinical development of CIA was scored by daily observation where the inflammation of all four paws was graded from 0 to 4 as described. 44 Each paw was graded, and the four scores were totaled so that the maximal possible score per mouse was 16. A total of 1 Â 10 6 hybridomas were injected intravenously on day 20. Animals were split into four groups of 20, receiving either no treatment, A2-pGCy (vector control), A2-pGCy.TN3 or A2-pGCy.TN3-Ck. Five animals from each group were killed at days 5, 14 and 30 for analysis of chemokine profiles, antigen reactivity and vector expression in DLN, spleen and paws. Paws were removed proximal to the ankle joint.
Detection of neutralizing antibodies
Cell supernatants taken from A2 hybridomas transduced with pGCy or pGCy.TN3-Ck, plus a hamster IgG1 (Santa Cruz Biotech) at a concentration of 1 mg/ml in PBS, were applied to white MAXIsorp ELISA plates (Nunc) (200 ml per well) and incubated overnight at 41C. The plates were washed six times with PBS, 0.05% Tween-20 (PBST), then rinsed with deionized water. Wells were blocked for 2 h with 200 ml of a blocking solution of 5% dried milk. Following blocking, 200 ml of a 10-fold dilution of sample serum in blocking solution was added, and the plates were incubated with agitation at room temperature for 2 h. After washing six times with PBST, and rinsing with deionized water, an anti-mouse IgG conjugated to horse radish peroxidase diluted 1:1000 in blocking solution was added to each well, and incubated for a further 1 h at room temperature. After washing six times with PBST, and rinsing with deionized water the ELISA was developed using the Supersignal ELISA Pico chemiluminescent detection system (Pierce).
Analysis of in vivo lymphocyte activity
Cells were harvested from spleen and DLN, and resuspended in RPMI, 10% FCS at a density of 5 Â 10 6 cells per ml. For analysis of cytokine profiles, harvested cells were incubated with 750 mg/ml denatured bovine CII for 48 or 72 h, the supernatant harvested and assayed by ELISA for IFN-g, TNF, IL-4 and IL-10. Lymphocyte proliferation was measured by incubating harvested cells with 0, 50 or 100 mg/ml denatured bovine CII for 48 or 72 h, and then pulsing the cells with 10 mCi tritiated thymidine (Amersham) for 16 h. Cells were then harvested and thymidine incorporation was determined on a scintillation counter (Perkin Elmer, Wellesley, MA, USA).
Determination of vector expression and cytokine profiles in the paw
Paws were removed from killed mice immediately proximal to the ankle joint and grouped according to disease score (0, 1+2 and 3+4). Paws were homogenized in Trizol (Gibco Invitrogen, Carlsbad, CA, USA), and the RNA was extracted according to the manufacturer's instructions. The extracted total RNA was stored at À801C until analysis. RT-PCR, using One-Step RT-PCR system (Qiagen, Valencia, CA, USA), was then used to detect YFP (5 0 primer, ATGGTGAGCAAGGGCGAGGA, 3 0 primer, TTACTTGTA CAGCTCGTCCA) and actin (5 0 primer, GTCGTACCCAGG CATTGTGATGG, 3 0 primer, GCAATGCCTGGGTA CATGGTGG). In all, 50 ng of total RNA was used per 25 ml reaction. With 40 PCR cycles, this was sensitive enough to detect YFP mRNA from a single cell.
For analysis of cytokine expression within the paws, the same RT-PCR system was used as described above, but with 30 cycles of PCR. The primers used were IL-1 (GTTCCTGACTTGTTTGAA, GGTGAAGTTGGACAT), IL-1 receptor antagonist (IL-1Ra) (GGCCTCCGCAGT CACCTAATCACTCT, TACTACTCGTCCTCCTGGAAG TAGAA), IL-4 (CATGGGAAAACTCCATGCTT, ATCG AAAAGCCCGAAAGAGT), IL-6 (GGTAGCTATGGTAC TCCA, GTGACAACCACGGCCTTCCCTACT), IFN-g (CCATCGGCTGACCTAGAGAA, GGAGGAGAAGC CCAGAACTT), TNF (CCCAAAGAATTCGGCTTATGA GCA, GATGGTGCAGTGCAAT).
Determination of chemokine expression in the paw by quantitative RT-PCR
Paws were homogenized in Trizol (Gibco Invitrogen, Carlsbad, CA, USA), and total RNA was extracted according to the manufacturer's instructions. First-strand cDNA was synthesized using random primers and MultiScribe reverse transcriptase (Applied Biosciences, Foster City, CA, USA) from 1 mg of each RNA sample. 0 -AAACATCCAGACCCAGAAAGGA-3 0 for MIP3b; Applied Biosciences, Foster City, CA, USA). SYBR Green PCR reagents were used (Applied Biosciences, Foster City, CA, USA) and the PCR was performed on a GeneAmp 5700 sequence detection system-stage 1: 2 min at 501C; stage 2: 10 min at 951C; stage 3: 40 cycles of 951C for 15 s plus 601C for 1 min (Applied Biosciences, Foster City, CA, USA). The data were analysed using SDS software (Applied Biosciences, Foster City, CA, USA) and the amount of product in each sample was calculated by reference to standard curves. Loading differences between samples were normalized using rRNA concentration, and rRNA was detected using TaqMan Ribosomal RNA Control Reagents (Applied Biosciences, Foster City, CA).
